Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)

NCT05732402 is registered in ClinicalTrials.gov with Alpine Immune Sciences, Inc. as lead sponsor.

NCT NCT05732402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05732402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
Lead sponsor
Alpine Immune Sciences, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 15, 2023
Completion date
March 2, 2028
Enrollment
72 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

anti-neutrophil cytoplasmic antibody-associated vasculitis, immunoglobulin a nephropathy, lupus nephritis, membranous nephropathy